Multiple myeloma differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Hannan Javed (talk | contribs) |
Hannan Javed (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Differentiating Multiple Myeloma from other Diseases== | ==Differentiating Multiple Myeloma from other Diseases== | ||
*The table below summarizes how to differentiate multiple myeloma from other conditions that have a similar presentation:<ref name="seer">{{Cite web | last = | first = | title = Myeloma - SEER Stat Fact Sheets | url = http://seer.cancer.gov/statfacts/html/mulmy.html | publisher = | date = | accessdate = 17 February 2014 }}</ref> | *The table below summarizes how to differentiate multiple myeloma from other conditions that have a similar presentation:<ref name="seer">{{Cite web | last = | first = | title = Myeloma - SEER Stat Fact Sheets | url = http://seer.cancer.gov/statfacts/html/mulmy.html | publisher = | date = | accessdate = 17 February 2014 }}</ref><ref name="pmid28934935">{{cite journal| author=Zuo QY, Wang H, Li W, Niu XH, Huang YH, Chen J et al.| title=Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients. | journal=BMC Musculoskelet Disord | year= 2017 | volume= 18 | issue= 1 | pages= 403 | pmid=28934935 | doi=10.1186/s12891-017-1756-1 | pmc=5609032 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28934935 }} </ref><ref name="pmid26401268">{{cite journal| author=Shaker JL, Albert C, Fritz J, Harris G| title=Recent developments in osteogenesis imperfecta. | journal=F1000Res | year= 2015 | volume= 4 | issue= F1000 Faculty Rev | pages= 681 | pmid=26401268 | doi=10.12688/f1000research.6398.1 | pmc=4566283 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26401268 }} </ref><ref name="pmid29299040">{{cite journal| author=Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, Murthy SN| title=The metabolism and significance of homocysteine in nutrition and health. | journal=Nutr Metab (Lond) | year= 2017 | volume= 14 | issue= | pages= 78 | pmid=29299040 | doi=10.1186/s12986-017-0233-z | pmc=5741875 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29299040 }} </ref> | ||
{| align="center" | {| align="center" | ||
|- | |- | ||
| Line 36: | Line 36: | ||
*[[Autologous bone marrow transplantation|Autologous stem cell transplantation]] | *[[Autologous bone marrow transplantation|Autologous stem cell transplantation]] | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Monoclonal gammopathy of undetermined significance]] ([[MGUS]])''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Monoclonal gammopathy of undetermined significance]] ([[MGUS]])''' | ||
|style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults | *[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults | ||
*Clonal [[plasma cell]] proliferation | *Clonal [[plasma cell]] proliferation | ||
|style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Asymptomatic]] | * [[Asymptomatic]] | ||
* [[Serum]] [[M protein]] of <30 g/L | * [[Serum]] [[M protein]] of <30 g/L | ||
| Line 46: | Line 46: | ||
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage | * No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage | ||
* | * | ||
|style="padding: 5px 5px; background: #F5F5F5;" |Observation | | style="padding: 5px 5px; background: #F5F5F5;" |Observation | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Asymptomatic Plasma Cell Myeloma''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Asymptomatic Plasma Cell Myeloma''' | ||
('''Smoldering''' and '''Indolent plasma cell myeloma''') | ('''Smoldering''' and '''Indolent plasma cell myeloma''') | ||
|style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults | *[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults | ||
*[[Malignant]] transformation of [[plasma cells]] | *[[Malignant]] transformation of [[plasma cells]] | ||
*Clonal [[plasma cell]] proliferation | *Clonal [[plasma cell]] proliferation | ||
|style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Asymptomatic]] | * [[Asymptomatic]] | ||
* [[Serum]] [[M protein]] of >30 g/L | * [[Serum]] [[M protein]] of >30 g/L | ||
* Greater than 10% [[plasma cells]] in the [[bone marrow]] | * Greater than 10% [[plasma cells]] in the [[bone marrow]] | ||
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage | * No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage | ||
|style="padding: 5px 5px; background: #F5F5F5;" |Observation | | style="padding: 5px 5px; background: #F5F5F5;" |Observation | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Plasma cell leukemia|Plasma Cell Leukemia]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Plasma cell leukemia|Plasma Cell Leukemia]]''' | ||
|style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults | * [[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults | ||
* [[Malignant]] transformation of [[plasma cells]] | * [[Malignant]] transformation of [[plasma cells]] | ||
|style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*[[Renal failure]] | *[[Renal failure]] | ||
*[[Hypercalcemia]] | *[[Hypercalcemia]] | ||
*[[Cytopenias]] | *[[Cytopenias]] | ||
*No [[bone]] lesions | *No [[bone]] lesions | ||
|style="padding: 5px 5px; background: #F5F5F5;" |[[Chemotherapy]] | | style="padding: 5px 5px; background: #F5F5F5;" |[[Chemotherapy]] | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Plasmacytoma]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Plasmacytoma]]''' | ||
|style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults | *[[Chromosomal aberration|Chromosomal aberrations]] or other [[Genetics|genetic]] insults | ||
*[[Malignant]] transformation of [[plasma cells]] | *[[Malignant]] transformation of [[plasma cells]] | ||
|style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Solitary bone [[plasmacytoma]] ([[bone]]) | * Solitary bone [[plasmacytoma]] ([[bone]]) | ||
* Extramedullary [[plasmacytoma]] ([[Soft tissue|soft tissues]]) | * Extramedullary [[plasmacytoma]] ([[Soft tissue|soft tissues]]) | ||
* Clinical manifestations related to [[tumor]] mass and compression [[symptoms]] | * Clinical manifestations related to [[tumor]] mass and compression [[symptoms]] | ||
|style="padding: 5px 5px; background: #F5F5F5;" |[[Surgery]] | | style="padding: 5px 5px; background: #F5F5F5;" |[[Surgery]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteoporosis]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteoporosis]]''' | ||
| Line 98: | Line 98: | ||
*[[RANKL|RANK ligand]] inhibitors ([[denosumab]]) | *[[RANKL|RANK ligand]] inhibitors ([[denosumab]]) | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteomalacia]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteomalacia]]''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Inadequate [[mineralization of bone]] | *Inadequate [[mineralization of bone]] | ||
| Line 126: | Line 126: | ||
*Citrus fruits | *Citrus fruits | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteogenesis imperfecta]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Osteogenesis imperfecta]]''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*[[Mutations]] in ''[[COL1A1]]'' or ''[[COL1A2]]'' | *[[Mutations]] in ''[[COL1A1]]'' or ''[[COL1A2]]'' | ||
| Line 139: | Line 139: | ||
*Genetic counseling for offspring | *Genetic counseling for offspring | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Homocystinuria]]''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Homocystinuria]]''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Deficiency of [[Cystathionine-beta-synthase|cystathionine ''beta'' synthase]] | *Deficiency of [[Cystathionine-beta-synthase|cystathionine ''beta'' synthase]] | ||
Revision as of 15:54, 1 November 2018
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma differential diagnosis |
|
Risk calculators and risk factors for Multiple myeloma differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: {}HMHJ} {AE} Haytham Allaham, M.D. [2] Shyam Patel [3]
Overview
Multiple myeloma must be differentiated from other causes of bone lesions such as osteoporosis, osteomalacia, scurvy, osteogenesis imperfecta, and homocystinuria. Each condition has unique causes, features, and treatment.
Differentiating Multiple Myeloma from other Diseases
- The table below summarizes how to differentiate multiple myeloma from other conditions that have a similar presentation:[1][2][3][4]
References
- ↑ "Myeloma - SEER Stat Fact Sheets". Retrieved 17 February 2014.
- ↑ Zuo QY, Wang H, Li W, Niu XH, Huang YH, Chen J; et al. (2017). "Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients". BMC Musculoskelet Disord. 18 (1): 403. doi:10.1186/s12891-017-1756-1. PMC 5609032. PMID 28934935.
- ↑ Shaker JL, Albert C, Fritz J, Harris G (2015). "Recent developments in osteogenesis imperfecta". F1000Res. 4 (F1000 Faculty Rev): 681. doi:10.12688/f1000research.6398.1. PMC 4566283. PMID 26401268.
- ↑ Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys TW, Murthy SN (2017). "The metabolism and significance of homocysteine in nutrition and health". Nutr Metab (Lond). 14: 78. doi:10.1186/s12986-017-0233-z. PMC 5741875. PMID 29299040.